This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
In average-risk adults, Cologuard Plus demonstrated sensitivities of 95% for CRC and 43% for advanced precancerous lesions at 94% specificity in the pivotal BLUE-C trial.
Medscape Medical News